Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vivus Inc (VVUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 101,885
  • Shares Outstanding, K 105,580
  • Annual Sales, $ 124,260 K
  • Annual Income, $ 23,300 K
  • 36-Month Beta 0.88
  • Price/Sales 0.82
  • Price/Cash Flow 2.30
  • Price/Book 18.63
  • Price/Earnings ttm 3.11
  • Earnings Per Share ttm 0.31
  • Most Recent Earnings -0.01 on 05/03/17
  • Next Earnings Date 11/08/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.86 +12.21%
on 09/06/17
1.02 -5.39%
on 09/18/17
-0.01 (-0.52%)
since 08/22/17
3-Month
0.86 +12.21%
on 09/06/17
1.32 -26.89%
on 07/11/17
-0.19 (-16.81%)
since 06/22/17
52-Week
0.86 +12.21%
on 09/06/17
1.47 -34.35%
on 12/07/16
-0.12 (-10.65%)
since 09/22/16

Most Recent Stories

More News
VIVUS Gives Rights to Alvogen in Korea for Anti-Obesity Drug

VIVUS, Inc. (VVUS) signed an agreement with Alvogen giving rights to the latter to market anti-obesity drug Qsymia in Korea for the treatment of chronic weight management or weight-related conditions.

VVUS : 0.96 (unch)
REGN : 432.72 (-0.17%)
ADRO : 10.80 (-1.82%)
ALXN : 142.82 (-0.07%)
VIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension

CAMPBELL, CA--(Marketwired - September 06, 2017) - VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing...

VVUS : 0.96 (unch)
VIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension

CAMPBELL, CA--(Marketwired - September 06, 2017) - VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing...

VVUS : 0.96 (unch)
VIVUS and Alvogen Announce Marketing Agreement for Qsymia(R) in the Republic of Korea

CAMPBELL, CA, and SAN GWANN, MALTA--(Marketwired - September 05, 2017) - VIVUS, Inc. (NASDAQ: VVUS) and Alvogen Malta Operations (ROW) Ltd, today announced an agreement under which Alvogen will market...

VVUS : 0.96 (unch)
VIVUS and Alvogen Announce Marketing Agreement for Qsymia(R) in the Republic of Korea

CAMPBELL, CA, and SAN GWANN, MALTA--(Marketwired - September 05, 2017) - VIVUS, Inc. (NASDAQ: VVUS) and Alvogen Malta Operations (ROW) Ltd, today announced an agreement under which Alvogen will market...

VVUS : 0.96 (unch)
VIVUS (VVUS) Down 19.8% Since Earnings Report: Can It Rebound?

VIVUS (VVUS) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

VVUS : 0.96 (unch)
Technical Insights on Biotech Stocks -- Grifols, Halozyme Therapeutics, Illumina, and VIVUS

If you want a Stock Review on GRFS, HALO, ILMN, or VVUS then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Thursday, benchmark US indices were...

ILMN : 201.41 (+0.58%)
VVUS : 0.96 (unch)
GRFS : 20.98 (+1.06%)
HALO : 16.78 (+1.08%)
VIVUS Announces Settlement with Dr. Reddy's Laboratories on Qsymia(R) Patent Litigation

CAMPBELL, CA--(Marketwired - August 30, 2017) - VIVUS, Inc. (NASDAQ: VVUS) announced today that it has entered into a settlement agreement with Dr. Reddy's Laboratories, S.A. and Dr. Reddy's Laboratories,...

VVUS : 0.96 (unch)
VIVUS Announces Settlement with Dr. Reddy's Laboratories on Qsymia(R) Patent Litigation

CAMPBELL, CA--(Marketwired - August 30, 2017) - VIVUS, Inc. (NASDAQ: VVUS) announced today that it has entered into a settlement agreement with Dr. Reddy's Laboratories, S.A. and Dr. Reddy's Laboratories,...

VVUS : 0.96 (unch)
Developments in the Erectile Dysfunction Markets

A research report by Life Science Intelligence (LSI), Erectile dysfunction (ED) is estimated to affect more than 150 million men worldwide and the number of men with ED is expected to double by the year...

VDRM : 0.0187 (-1.06%)
EAPH : 0.0240 (-0.83%)
VVUS : 0.96 (unch)
APRI : 1.68 (+1.51%)
CELZ : 0.2000 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity...

See More

Support & Resistance

2nd Resistance Point 0.97
1st Resistance Point 0.97
Last Price 0.96
1st Support Level 0.95
2nd Support Level 0.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.